Hélène Cabanas: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (Text replacement - "<ref>{{Cite journal|last=Marshall-Gradisnik|first=Sonya|author-link=Sonya Marshall-Gradisnik|last2=Fretel|first2=Marshall|last3=Eaton|first3=Natalie|last4=Cabanas|first4=Helene|last5=Balinas|first5=Cassandra|last6=Gopalan|first6=Vin...)
Line 11: Line 11:
*2019, [[Transient receptor potential melastatin 2]] channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients<ref name="Balinas2019">{{Cite journal|last=Balinas|first=Cassandra|author-link=Cassandra Balinas|last2=Cabanas|first2=Hélène|author-link2=Hélène Cabanas|last3=Staines|first3=Donald|author-link3=Donald Staines|last4=Marshall-Gradisnik|first4=Sonya|author-link4=Sonya Marshall-Gradisnik|date=2019-12-03|title=Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients|url=https://doi.org/10.1186/s12967-019-02155-4|journal=Journal of Translational Medicine|volume=17|issue=1|pages=401|doi=10.1186/s12967-019-02155-4|issn=1479-5876|pmc =  6891975|pmid=31796045|access-date=|quote=|via=}}</ref> - [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-02155-4 (Full text)]
*2019, [[Transient receptor potential melastatin 2]] channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients<ref name="Balinas2019">{{Cite journal|last=Balinas|first=Cassandra|author-link=Cassandra Balinas|last2=Cabanas|first2=Hélène|author-link2=Hélène Cabanas|last3=Staines|first3=Donald|author-link3=Donald Staines|last4=Marshall-Gradisnik|first4=Sonya|author-link4=Sonya Marshall-Gradisnik|date=2019-12-03|title=Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients|url=https://doi.org/10.1186/s12967-019-02155-4|journal=Journal of Translational Medicine|volume=17|issue=1|pages=401|doi=10.1186/s12967-019-02155-4|issn=1479-5876|pmc =  6891975|pmid=31796045|access-date=|quote=|via=}}</ref> - [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-02155-4 (Full text)]


* 2018, Decreased Expression of [[Transient receptor potential melastatin 3|TRPM3]] and [[muscarinic acetylcholine M3 receptor|mAChRM3]] in the Small Intestine in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref>{{Cite journal|last=Marshall-Gradisnik|first=Sonya|author-link=Sonya Marshall-Gradisnik|last2=Fretel|first2=Marshall|last3=Eaton|first3=Natalie|last4=Cabanas|first4=Helene|last5=Balinas|first5=Cassandra|last6=Gopalan|first6=Vinod|last7=Petersen|first7=Daniel|author-link7=Daniel Peterson|last8=Passmore|first8=Rachel|last9=Tang|first9=Kevin|last10= Haque|first10=Mazhar|author-link10=|last11=Lam|first11=Alfred |author-link11=|last12=Staines|first12=Donald|author-link12=Donald Staines|date=2018-05-31|title=Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|url=http://www.scirp.org/journal/PaperInformation.aspx?PaperID=85005&#abstract|journal=International Journal of Clinical Medicine|language=en|volume=09|issue=05|pages=467|doi=10.4236/ijcm.2018.95040|via=|pmc=|pmid=|quote=|author-link2=|access-date=|author-link3=|author-link4=Hélène Cabanas|author-link5=}}</ref> - [http://file.scirp.org/Html/11-2101759_85005.htm (Full text)]
* 2018, Decreased Expression of [[Transient receptor potential melastatin 3|TRPM3]] and [[muscarinic acetylcholine M3 receptor|mAChRM3]] in the Small Intestine in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref name="Gradisnik2018">{{Cite journal|last=Marshall-Gradisnik|first=Sonya|author-link=Sonya Marshall-Gradisnik|last2=Fretel|first2=Marshall|author-link2=|last3=Eaton|first3=Natalie|author-link3=Natalie Eaton-Fitch|last4=Cabanas|first4=Helene|author-link4=Hélène Cabanas|last5=Balinas|first5=Cassandra|author-link5=Cassandra Balinas|last6=Gopalan|first6=Vinod|last7=Petersen|first7=Daniel|author-link7=Daniel Peterson|last8=Passmore|first8=Rachel|last9=Tang|first9=Kevin|last10=Haque|first10=Mazhar|author-link10=|last11=Lam|first11=Alfred|author-link11=|last12=Staines|first12=Donald|author-link12=Donald Staines|date=2018-05-31|title=Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|url=http://www.scirp.org/journal/PaperInformation.aspx?PaperID=85005&#abstract|journal=International Journal of Clinical Medicine|language=en|volume=09|issue=05|pages=467|doi=10.4236/ijcm.2018.95040|via=|pmc=|pmid=|quote=|author-link2=|access-date=|author-link3=|author-link4=Hélène Cabanas|author-link5=}}</ref> - [http://file.scirp.org/Html/11-2101759_85005.htm (Full text)]
* 2018, A systematic review of enteric [[dysbiosis]] in chronic fatigue syndrome/myalgic encephalomyelitis<ref>{{Cite journal|last=Du Preez|first=S.|author-link=|last2=Corbitt|first2=M.|author-link2=|last3=Cabanas|first3=H.|author-link3=Hélène Cabanas|last4=Eaton|first4=N.|author-link4=|last5=Staines|first5=D.|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=S.|author-link6=Sonya Marshall-Gradisnik|date=2018-12-20|title=A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis|url=https://doi.org/10.1186/s13643-018-0909-0|journal=Systematic Reviews|volume=7|issue=1|pages=241|doi=10.1186/s13643-018-0909-0|issn=2046-4053|pmc=|pmid=30572962|quote=|via=}}</ref> - [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-018-0909-0 (Full text)]
* 2018, A systematic review of enteric [[dysbiosis]] in chronic fatigue syndrome/myalgic encephalomyelitis<ref>{{Cite journal|last=Du Preez|first=S.|author-link=|last2=Corbitt|first2=M.|author-link2=|last3=Cabanas|first3=H.|author-link3=Hélène Cabanas|last4=Eaton|first4=N.|author-link4=|last5=Staines|first5=D.|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=S.|author-link6=Sonya Marshall-Gradisnik|date=2018-12-20|title=A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis|url=https://doi.org/10.1186/s13643-018-0909-0|journal=Systematic Reviews|volume=7|issue=1|pages=241|doi=10.1186/s13643-018-0909-0|issn=2046-4053|pmc=|pmid=30572962|quote=|via=}}</ref> - [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-018-0909-0 (Full text)]
* 2018, [[Rituximab]] impedes [[natural killer cell]] function in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] patients: A pilot in vitro investigation<ref>{{Cite journal|title=Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation|url=https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-018-0203-8|journal=BMC Pharmacology and Toxicology|date=Dec 2018|issn=2050-6511|pmc=5870391|pmid=29587879|pages=12|volume=19|issue=1|doi=10.1186/s40360-018-0203-8|language=en|first=Natalie|last=Eaton|first2=Hélène|last2=Cabanas|first3=Cassandra|last3=Balinas|first4=Anne|last4=Klein|first5=Donald|last5=Staines|first6=Sonya|last6=Marshall-Gradisnik|quote=|author-link=|author-link2=Hélène Cabanas|access-date=|author-link3=|author-link4=|author-link5=Donald Staines|author-link6=Sonya Marshall-Gradisnik|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870391/ (Full Text)]
* 2018, [[Rituximab]] impedes [[natural killer cell]] function in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] patients: A pilot in vitro investigation<ref>{{Cite journal|title=Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation|url=https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-018-0203-8|journal=BMC Pharmacology and Toxicology|date=Dec 2018|issn=2050-6511|pmc=5870391|pmid=29587879|pages=12|volume=19|issue=1|doi=10.1186/s40360-018-0203-8|language=en|first=Natalie|last=Eaton|first2=Hélène|last2=Cabanas|first3=Cassandra|last3=Balinas|first4=Anne|last4=Klein|first5=Donald|last5=Staines|first6=Sonya|last6=Marshall-Gradisnik|quote=|author-link=|author-link2=Hélène Cabanas|access-date=|author-link3=|author-link4=|author-link5=Donald Staines|author-link6=Sonya Marshall-Gradisnik|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870391/ (Full Text)]

Revision as of 22:18, September 30, 2022

Hélène Cabanas, PhD, is a Cell physiologist participating in a post-doctorate fellowship at the School of Medical Sciences, Griffith Health, Griffith University, Australia.[1] She is a member of the National Centre for Neuroimmunology and Emerging Disease (NCNED), an Australian research group led by Professors Sonya Marshall-Gradisnik and Donald Staines.[2] Her research focuses on cellular calcium pathway signalling and their implications in physiological and pathophysiological processes in hopes of understanding the pathomechanism of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME).[2]

Notable studies[edit | edit source]

  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[3] - (Full text)
  • 2021, Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[4] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients[5] - (Full text)
  • 2019, A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)[6] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[7] - (Abstract)
  • 2019, Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients[8] - (Full text)

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Hélène Cabanas". LinkedIn. Retrieved October 21, 2019.
  2. 2.0 2.1 "National Centre for Neuroimmunology and Emerging Diseases". www.griffith.edu.au. Retrieved October 21, 2019.
  3. Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  4. Maksoud, Rebekah; Eaton-Fitch, Natalie; Matula, Michael; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (May 2021). "Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Healthcare. 9 (5): 568. doi:10.3390/healthcare9050568.
  5. Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (1). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  6. Corbitt, Matthew; Eaton-Fitch, Natalie; Staines, Donald; Cabanas, Hélène; Marshall-Gradisnik, Sonya (December 2019). "A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)". BMC Neurology. 19 (1). doi:10.1186/s12883-019-1433-0. ISSN 1471-2377. PMID 31445522.
  7. Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  8. Balinas, Cassandra; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (December 3, 2019). "Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients". Journal of Translational Medicine. 17 (1): 401. doi:10.1186/s12967-019-02155-4. ISSN 1479-5876. PMC 6891975. PMID 31796045.
  9. Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  10. Du Preez, S.; Corbitt, M.; Cabanas, H.; Eaton, N.; Staines, D.; Marshall-Gradisnik, S. (December 20, 2018). "A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis". Systematic Reviews. 7 (1): 241. doi:10.1186/s13643-018-0909-0. ISSN 2046-4053. PMID 30572962.
  11. Eaton, Natalie; Cabanas, Hélène; Balinas, Cassandra; Klein, Anne; Staines, Donald; Marshall-Gradisnik, Sonya (December 2018). "Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation". BMC Pharmacology and Toxicology. 19 (1): 12. doi:10.1186/s40360-018-0203-8. ISSN 2050-6511. PMC 5870391. PMID 29587879.
  12. Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (1). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551.